NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share of Y-mAbs that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat
Related Questions
How does this transaction compare to recent M&A activity in the biotech sector in terms of valuation multiples?
Will the sale affect any outstanding debt or convertible securities held by Y‑MABS?
Is the $8.60 cash offer per share a premium or discount to Y‑MABS' current market price?
Could legal or regulatory challenges force a renegotiation of the transaction terms?
How will the investigation by the former Attorney General affect the likelihood of the sale closing?
What are the potential upside or downside scenarios for shareholders if the deal is aborted or proceeds at a different price?
What is the expected timeline for the sale to be finalized, and could the investigation delay it?
How might the proposed sale impact Y‑MABS' trading volume and volatility in the short term?
What are the implications for Y‑MABS' existing pipeline and future cash flow if the company is acquired by SERB Pharmaceuticals?
Are there any alternative suitors or competing offers that could emerge as a result of the investigation?